Acetaminophen to treat fever in intensive care unit patients with likely infection: a response from the author of the HEAT trial

The HEAT trial was a phase 2b randomized, double-blind, placebo-controlled trial designed to provide preliminary data on the safety and efficacy of using intravenous acetaminophen (paracetamol) to treat fever in intensive care unit (ICU) patients with likely infection (1,2). The trial and its interpretation in the wider context of existing literature on fever control were discussed in commentaries (3,4) and a perspective (5) published in recent issues.